Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05271604 is registered in ClinicalTrials.gov with BioAtla, Inc. as lead sponsor.

NCT NCT05271604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05271604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
BioAtla, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 13, 2022
Completion date
September 22, 2025
Enrollment
42 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, metastatic cancer, metastatic squamous cell carcinoma of the head and neck, recurrent squamous cell carcinoma of the head and neck, squamous cell carcinoma of head and neck